Do analysts recommend PRFX or DRMA?

Dermata Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 646.27%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dermata Therapeutics is more favorable than PainReform. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PRFX or DRMA more profitable?

PainReform's return on equity of 0.00% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Dermata Therapeutics N/A -127.91% -105.05%

Do analysts recommend PRFX or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PRFX or ENVB more profitable?

PainReform's return on equity of 0.00% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Enveric Biosciences N/A -220.97% -177.47%

Do analysts recommend GOVX or PRFX?

GeoVax Labs currently has a consensus target price of $150.00, indicating a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher possible upside, research analysts plainly believe GeoVax Labs is more favorable than PainReform. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GOVX or PRFX more profitable?

PainReform's return on equity of 0.00% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -709.52% -399.33% PainReform N/A N/A N/A

Do analysts rate RDHL or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, RDHL or PRFX?

Redhill Biopharma has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Redhill Biopharma $290K 14.54 -$430K $1.05 thousand 0.00 PainReform $20K 59.16 -$5.02M -$736.66 N/A

Is RDHL or PRFX more profitable?

Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A PainReform N/A N/A N/A

Do analysts prefer PRFX or RNAZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PRFX or RNAZ more profitable?

PainReform's return on equity of 0.00% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A TransCode Therapeutics N/A -875.35% -50.36%

PainReform (PRFX) Competitors

$1.36 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.38 +0.01 (+1.10%)

As of 07/2/2026 07:58 PM Eastern

Compare

PRFX vs. DRMA, ENVB, GOVX, RDHL, and RNAZ

Should you buy PainReform stock or one of its competitors? MarketBeat compares PainReform with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PainReform include Dermata Therapeutics (DRMA), Enveric Biosciences (ENVB), GeoVax Labs (GOVX), Redhill Biopharma (RDHL), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry.

How does PainReform compare to Dermata Therapeutics?

PainReform (NASDAQ:PRFX) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, PainReform's average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company	Overall Sentiment
PainReform	Neutral
Dermata Therapeutics	Neutral

Dermata Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 646.27%. Given Dermata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dermata Therapeutics is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PainReform has higher revenue and earnings than Dermata Therapeutics. Dermata Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	59.16	-$5.02M	-$736.66	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A

PainReform's return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Dermata Therapeutics	N/A	-127.91%	-105.05%

PainReform has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

37.3% of PainReform shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 34.4% of PainReform shares are held by insiders. Comparatively, 21.9% of Dermata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

PainReform beats Dermata Therapeutics on 8 of the 12 factors compared between the two stocks.

How does PainReform compare to Enveric Biosciences?

PainReform (NASDAQ:PRFX) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

PainReform has higher revenue and earnings than Enveric Biosciences. Enveric Biosciences is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	59.16	-$5.02M	-$736.66	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

PainReform's return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Enveric Biosciences	N/A	-220.97%	-177.47%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

37.3% of PainReform shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PainReform has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

In the previous week, PainReform's average media sentiment score of 0.00 beat Enveric Biosciences' score of -0.35 indicating that PainReform is being referred to more favorably in the media.

Company	Overall Sentiment
PainReform	Neutral
Enveric Biosciences	Neutral

Summary

PainReform beats Enveric Biosciences on 8 of the 10 factors compared between the two stocks.

How does PainReform compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, GeoVax Labs had 2 more articles in the media than PainReform. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for PainReform. GeoVax Labs' average media sentiment score of 0.49 beat PainReform's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Neutral
PainReform	Neutral

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by insiders. Comparatively, 34.4% of PainReform shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GeoVax Labs currently has a consensus target price of $150.00, indicating a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher possible upside, research analysts plainly believe GeoVax Labs is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform's return on equity of 0.00% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
PainReform	N/A	N/A	N/A

GeoVax Labs has a beta of 3.68, meaning that its stock price is 268% more volatile than the broader market. Comparatively, PainReform has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

PainReform has lower revenue, but higher earnings than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.66	-$21.47M	-$19.12	N/A
PainReform	$20K	59.16	-$5.02M	-$736.66	N/A

Summary

GeoVax Labs and PainReform tied by winning 7 of the 14 factors compared between the two stocks.

How does PainReform compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Redhill Biopharma has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00
PainReform	$20K	59.16	-$5.02M	-$736.66	N/A

In the previous week, Redhill Biopharma's average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
PainReform	Neutral

7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
PainReform	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has a beta of 4.98, suggesting that its stock price is 398% more volatile than the broader market. Comparatively, PainReform has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Summary

Redhill Biopharma beats PainReform on 5 of the 8 factors compared between the two stocks.

How does PainReform compare to TransCode Therapeutics?

PainReform (NASDAQ:PRFX) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

In the previous week, TransCode Therapeutics had 1 more articles in the media than PainReform. MarketBeat recorded 1 mentions for TransCode Therapeutics and 0 mentions for PainReform. PainReform's average media sentiment score of 0.00 equaled TransCode Therapeutics'average media sentiment score.

Company	Overall Sentiment
PainReform	Neutral
TransCode Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform has higher revenue and earnings than TransCode Therapeutics. TransCode Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	59.16	-$5.02M	-$736.66	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A

37.3% of PainReform shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

PainReform's return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
TransCode Therapeutics	N/A	-875.35%	-50.36%

PainReform has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

Summary

PainReform beats TransCode Therapeutics on 7 of the 10 factors compared between the two stocks.

Get PainReform News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRFX vs. The Competition

Export

Metric	PainReform	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.18M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	0.00	20.06	28.02	24.70
Price / Sales	59.16	360.33	540.37	99.49
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.06	4.32	10.96	6.46
Net Income	-$5.02M	$64.45M	$3.57B	$337.01M
7 Day Performance	-9.93%	2.97%	2.12%	1.69%
1 Month Performance	-14.47%	6.83%	5.25%	3.81%
1 Year Performance	-81.03%	29.07%	33.29%	23.90%

PainReform Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRFX PainReform	0.6855 of 5 stars	$1.36 flat	N/A	-81.0%	$1.18M	$20K	N/A	4
DRMA Dermata Therapeutics	2.6185 of 5 stars	$1.21 -1.6%	$10.00 +726.4%	-79.9%	$4.87M	N/A	N/A	8	Positive News
ENVB Enveric Biosciences	0.5205 of 5 stars	$1.31 -3.0%	N/A	-90.4%	$4.82M	N/A	N/A	20	Short Interest Increase Gap Up
GOVX GeoVax Labs	2.6784 of 5 stars	$1.38 +7.0%	$150.00 +10,769.6%	-90.1%	$4.79M	$2.49M	N/A	10
RDHL Redhill Biopharma	1.3312 of 5 stars	$0.91 -1.8%	N/A	-59.7%	$4.72M	$286K	0.00	210	Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRFX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PainReform (PRFX) Competitors

PRFX vs. DRMA, ENVB, GOVX, RDHL, and RNAZ

How does PainReform compare to Dermata Therapeutics?

Summary

How does PainReform compare to Enveric Biosciences?

Summary

How does PainReform compare to GeoVax Labs?

Summary

How does PainReform compare to Redhill Biopharma?

Summary

How does PainReform compare to TransCode Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PainReform (PRFX) Competitors

PRFX vs. DRMA, ENVB, GOVX, RDHL, and RNAZ

How does PainReform compare to Dermata Therapeutics?

Does the media refer more to PRFX or DRMA?

Do analysts recommend PRFX or DRMA?

Which has preferable valuation and earnings, PRFX or DRMA?

Is PRFX or DRMA more profitable?

Which has more volatility & risk, PRFX or DRMA?

Do institutionals and insiders hold more shares of PRFX or DRMA?

Summary

How does PainReform compare to Enveric Biosciences?

Which has stronger earnings & valuation, PRFX or ENVB?

Is PRFX or ENVB more profitable?

Do analysts recommend PRFX or ENVB?

Do institutionals & insiders hold more shares of PRFX or ENVB?

Which has more volatility and risk, PRFX or ENVB?

Does the media refer more to PRFX or ENVB?

Summary

How does PainReform compare to GeoVax Labs?

Does the media refer more to GOVX or PRFX?

Do insiders & institutionals hold more shares of GOVX or PRFX?

Do analysts recommend GOVX or PRFX?

Is GOVX or PRFX more profitable?

Which has more risk & volatility, GOVX or PRFX?

Which has better valuation & earnings, GOVX or PRFX?

Summary

How does PainReform compare to Redhill Biopharma?

Which has preferable valuation & earnings, RDHL or PRFX?

Does the media refer more to RDHL or PRFX?

Do insiders & institutionals hold more shares of RDHL or PRFX?

Is RDHL or PRFX more profitable?

Do analysts rate RDHL or PRFX?

Which has more volatility & risk, RDHL or PRFX?

Summary

How does PainReform compare to TransCode Therapeutics?

Does the media favor PRFX or RNAZ?

Do analysts prefer PRFX or RNAZ?

Which has preferable earnings & valuation, PRFX or RNAZ?

Do insiders and institutionals hold more shares of PRFX or RNAZ?

Is PRFX or RNAZ more profitable?

Which has more volatility & risk, PRFX or RNAZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools